On July 12, the House passed, by voice vote, H.R. 2430, the FDA Reauthorization Act of 2017. The Energy and Commerce Committee approved the legislation on June 7 (see The Source, 6/9/17).
The bill, sponsored by Rep. Greg Walden (R-OR), would expand user fees for prescription drugs, medical devices, generic drugs, and biosimilar products. The measure also would direct the secretary of Health and Human Services to hold a public meeting to discuss, among other topics, “the impact of exclusion criteria on the enrollment in clinical trials of particular populations, including infants and children, and pregnant and lactating women.”
